In addition to Hh hyperactivation, the overexpression of Histone deacetylase 6 (HDAC6) in GBM tumor promotes cell proliferation and TMZ resistance [14,15,16], indicating that HDAC6 targeting could represent a possible therapeutic strategy to counteract GBM progression. This evidence concerns the gene HDAC6 and glioblastoma.